Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN10 in healthy subjects and plaque psoriasis
NCT06143371Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Aug 2023
- Primary completion
- Nov 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CAN10 in plaque psoriasis, sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Safety and Tolerability of single and multiple ascending doses of CAN10. Started Aug 2023; status: completed.
02
Drugs
CAN10
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06143371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06143371.